Market cap
$633 Mln
Recently Viewed
Clear AllMarket cap
$633 Mln
Revenue (TTM)
$20 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.7
Debt to Equity
0
Book Value
$--
EPS
$-1
Face value
--
Shares outstanding
130,822,000
CFO
£-246.09 Mln
EBITDA
£-530.66 Mln
Net Profit
£-412.56 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Exscientia Ltd ADR (EXAI)
| -24.5 | -7.1 | -11.8 | -20.7 | -38.2 | -- | -- |
|
BSE Sensex*
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Exscientia Ltd ADR (EXAI)
| 20.3 | -73.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is... currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. Read more
Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
Dr. David Hallett Ph.D.
Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
Dr. David Hallett Ph.D.
Headquarters
Oxford
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Exscientia Ltd ADR (EXAI) is $4.84 (NASDAQ) as of 20-Nov-2024 09:30 EDT. Exscientia Ltd ADR (EXAI) has given a return of -38.24% in the last 3 years.
Since, TTM earnings of Exscientia Ltd ADR (EXAI) is negative, P/E ratio is not available.
The P/B ratio of Exscientia Ltd ADR (EXAI) is 1.95 times as on 20-Nov-2024, a 55 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-5.53
|
2.25
|
|
2022
|
-5.67
|
1.40
|
|
2021
|
-65.40
|
4.21
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Exscientia Ltd ADR (EXAI) are Rs -- and Rs -- as of 05-May-2026.
Exscientia Ltd ADR (EXAI) has a market capitalisation of $ 633 Mln as on 20-Nov-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Exscientia Ltd ADR (EXAI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.